Cortexyme (NASDAQ:CRTX) Share Price Passes Above 200 Day Moving Average - What's Next?

Key Points

• Cortexyme, Inc. (NASDAQ:CRTX)'s share price has surpassed its 200-day moving average, which stands at $1.42, with shares trading as high as $1.95.
• The company's stock increased by 7.9%, closing at $1.92 with a trading volume of 568,397 shares.
• Cortexyme is a clinical-stage biopharmaceutical company focusing on developing therapeutics for Alzheimer's and other degenerative diseases, with its lead drug candidate currently in Phase II/III clinical trials.

Cortexyme, Inc. (NASDAQ:CRTX - )'s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.42 and traded as high as $1.95. Cortexyme shares last traded at $1.92, with a volume of 568,397 shares trading hands.

Cortexyme Stock Up 7.9%

The business has a 50 day moving average of $1.64 and a 200 day moving average of $1.42. The company has a market capitalization of $57.89 million, a P/E ratio of -0.65 and a beta of 1.40.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.